# Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

> **NCT00444639** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Triptorelin (Decapeptyl®)

## Key facts

- **NCT ID:** NCT00444639
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2008-02
- **Final completion:** 2008-06
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00444639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00444639, "Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00444639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*